Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of “Buy” by Brokerages

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have been given an average recommendation of “Buy” by the six ratings firms that are covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have covered the stock in the last year is $29.50.

Several research firms recently commented on CPRX. Truist Financial boosted their price target on Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Citigroup increased their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. HC Wainwright increased their price objective on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, StockNews.com raised Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th.

Catalyst Pharmaceuticals Stock Up 0.3 %

Shares of NASDAQ:CPRX opened at $21.41 on Friday. The company has a market cap of $2.53 billion, a P/E ratio of 39.65, a P/E/G ratio of 3.18 and a beta of 0.76. Catalyst Pharmaceuticals has a 52 week low of $11.89 and a 52 week high of $21.85. The business has a fifty day simple moving average of $20.34 and a 200-day simple moving average of $17.56.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The firm had revenue of $122.71 million during the quarter, compared to the consensus estimate of $111.76 million. Sell-side analysts expect that Catalyst Pharmaceuticals will post 1.82 earnings per share for the current fiscal year.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Steve Miller sold 150,000 shares of the business’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the transaction, the insider now directly owns 675,124 shares in the company, valued at $13,738,773.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Steve Miller sold 150,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $20.35, for a total value of $3,052,500.00. Following the transaction, the insider now directly owns 675,124 shares in the company, valued at approximately $13,738,773.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 201,058 shares of company stock worth $4,018,188. Company insiders own 11.00% of the company’s stock.

Institutional Trading of Catalyst Pharmaceuticals

A number of large investors have recently made changes to their positions in CPRX. GAMMA Investing LLC increased its holdings in Catalyst Pharmaceuticals by 72.9% during the 1st quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 819 shares in the last quarter. nVerses Capital LLC acquired a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at about $50,000. CWM LLC lifted its stake in Catalyst Pharmaceuticals by 686.5% in the 2nd quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 3,549 shares during the last quarter. Meeder Asset Management Inc. bought a new position in Catalyst Pharmaceuticals in the 2nd quarter valued at about $70,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Catalyst Pharmaceuticals in the 2nd quarter valued at about $153,000. Institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.